The University Retina Clinical Trial Program is a comprehensive program that is aimed at helping patients with conditions using the latest research advances. University Retina is proud to have one of the largest clinical trial programs in the United States for retinal and macular conditions.
If you are interested in learning more or participating in a clinical trial for macular or retinal disease in Chicagoland, please call us at (708) 687-2222 or email us at email@example.com. Thank you.
Veeral S. Sheth, MD, MBA, FACS
Karen Zwicky, COA
Clinical trials are research studies of macular or retinal diseases that allow patients to participate in experimental, research treatments for diseases of the macula or retina that are not offered to the general public. Clinical trials are generally sponsored by pharmaceutical companies, governmental agencies, or non-profit institutions. These therapies are generally not currently approved by the Food and Drug Administration (FDA) but data from these studies is often used to help obtain FDA approval.
Participation in clinical trials is never mandatory and only if you wish to participate. University Retina has one of the largest clinical trial programs in the United States and we participate in clinical trials in order to be able to offer our patients with the latest therapies available for macular diseases and retinal diseases in Chicagoland.
Patients that are interested in clinical trials should contact us to schedule an appointment at (708) 687-2222. Please set up an appointment to be evaluated if you are interested in participating and we will determine whether you qualify for the trial.
Please note that not everyone who wishes to participate will be eligible to participate in the trial, as the criteria for inclusion in the trial are often very strict.
Regardless of whether you are able to participate or not, the University Retina team is committed to helping all of our patients with their retinal care.
OPH1004 - A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
clinicaltrials.gov Clinical Trials ID: NCT01940887
CAPELLA - R2176-3-AMD-1417 - Study of Intravitreal REGN2176-3 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
clinicaltrials.gov Clinical Trials ID: NCT02418754
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
clinicaltrials.gov Clinical Trials ID: NCT02355028
CHROMA - GX29176 - A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
clinicaltrials.gov Clinical Trials ID: NCT02247479
DRCR Protocol V - Treatment for CI-DME in Eyes With Very Good VA Study
clinicaltrials.gov Clinical Trials ID: NCT01909791
PALADIN - Phase 4 IOP Signals Associated With ILUVIEN®
clinicaltrials.gov Clinical Trials ID: NCT02424019
Clinical Trials for Vitreomacular Adhesion - NO LONGER RECRUITING
ORBIT - Ocriplasmin Research to Better Inform Treatment
clinicaltrials.gov Clinical Trials ID: NCT02079883
Clinical Trials for Wet Age Related Macular Degeneration (Wet AMD) - NO LONGER RECRUITING
OPH1005 - Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
clinicaltrials.gov Clinical Trials ID: NCT02214628
OPH1006 - An 18 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
clinicaltrials.gov Clinical Trials ID: NCT02387957